12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GS-7977/GS-5885: Phase I started

Gilead announced in its 2Q12 earnings conference call that it began a Phase I bioavailability trial to evaluate GS-7977/GS-5885 in patients with HCV genotype 1 infection. The company said if the Phase I data show adequate exposure of the compounds, it plans to begin a Phase III trial next quarter...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >